<DOC>
	<DOCNO>NCT00193336</DOCNO>
	<brief_summary>Because demonstrate single agent activity excellent tolerability patient refractory non-small cell lung cancer , ZD1839 may benefit first-line treatment patient advance non-small cell lung cancer poor performance status . In phase II trial , investigate single agent activity first-line ZD1839 patient advance non-small cell lung cancer poor performance status</brief_summary>
	<brief_title>Iressa Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : - ZD1839</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>To include study , must meet following criterion : Biopsy proven nonsmall cell lung cancer Recurrent nonsmall cell lung cancer previous surgery radiation Advanced disease ( stage IIIb IV ) No previous chemotherapy biological therapy Require significant assistance activity daily live Measurable disease Adequate bone marrow , liver kidney function Give write informed consent You participate study follow apply : Brain metastasis Meningeal metastasis Other uncontrolled malignancy Women pregnant lactate No measurable disease outside previous radiation therapy field Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>NSCLC Lung Cancer</keyword>
	<keyword>Non Small Cell Lung Cancer</keyword>
</DOC>